Pregabalin Zentiva

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

pregabalin

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Anti-epilettiċi,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

Awtorizzat

Authorization date:

2015-07-17

Patient Information leaflet

                                50
B.
FULJETT TA’ TAGĦRIF
51
FULJETT TA’ TAGĦRIF
:
INFORMAZZJONI GĦALL
-UTENT
PREGABALIN ZENTIVA 25 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 50 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 75 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 100 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 150 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 200 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 225 MG KAPSULI IBSIN
PREGABALIN ZENTIVA 300 MG KAPSULI IBSIN
pregabalin
AQRA SEW DAN IL-
FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL
-
MEDIĊINA PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK
.
-
Żomm dan il
-
fuljett. Jista’ jkollok bżonn terġa’ taqrah
.
-
Jekk ikollok
xi mistoqsija oħra
, staqsi lit-tabib jew lill-
ispiżjar tiegħek
.
-
Din il-
mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha lil
persuni oħra. Tista’
tagħmlilhom il
-
ħsara, anki jekk ikollhom l
-
istess sinjali ta’ mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-
ispiżjar
tiegħek
. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Pregabalin Zentiva
u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu
Pregabalin Zentiva
3.
Kif għandek tieħu
Pregabalin Zentiva
4.
Effetti sekondarji possibbli
5.
Kif taħżen
Pregabalin Zentiva
6.
Kontenut tal-
pakkett u informazzjoni oħra
1.
X’INHU PREGABALIN ZENTIVA U GĦALXIEX JINTUŻA
Pregabalin Zentiva
jappartjeni għal
grupp ta’ mediċini li jintużaw għall
-kura tal-epilessija, l-
uġigħ
nevrotiku u d-disturb ta’ ansjetà
ġ
eneralizzata (GAD - _generalised anxiety disorder_) fl-adulti.
UĠIGĦ NEVROTIKU PERIFERALI U ĊENTRALI
Pregabalin Zentiva jintuża sabiex jiġi kkurat uġigħ fit
-
tul ta’ żmien ikkawżat minn ħsara fin
-nervituri.
Hemm numru ta' mard li jista' jikkaġuna wġigħ newropatiku
periferali, bħad
-dijabete jew il-
ħruq ta’
Sant’Antnin. Is-
sensazzjonijiet ta' uġigħ li wieħed
iħoss
ħ
jistgħu jiġu deskritti bħala sħana, ħruq,
tektik, uġigħ li jiġri minn parti għal oħra tal
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-
KARATTERISTIĊI TAL
-PRODOTT
2
1.
ISEM IL-
PRODOTT MEDIĊINALI
Pregabalin Zentiva 25 mg kapsuli ibsin
Pregabalin Zentiva 50 mg kapsuli ibsin
Pregabalin Zentiva 75 mg kapsuli ibsin
Pregabalin Zentiva 100 mg kapsuli ibsin
Pregabalin Zentiva 150 mg kapsuli ibsin
Pregabalin Zentiva 200 mg kapsuli ibsin
Pregabalin Zentiva 225 mg kapsuli ibsin
Pregabalin Zentiva 300 mg kapsuli ibsin
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Pregabalin Zentiva 25 mg kapsuli ibsin
Kull kapsula iebsa fiha 25 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 47.57 mg lactose monohydrate.
Pregabalin Zentiva 50 mg kapsuli ibsin
Kull kapsula iebsa fiha 50 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 5 mg lactose monohydrate.
Pregabalin Zentiva 75 mg kapsuli ibsin
Kull kapsula iebsa fiha 75 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 7.5 mg lactose monohydrate.
Pregabalin Zentiva 100 mg kapsuli ibsin
Kull kapsula iebsa fiha 100 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 10 mg lactose monohydrate.
Pregabalin Zentiva 150 mg kapsuli ibsin
Kull kapsula iebsa fiha 150 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 15 mg lactose monohydrate.
Pregabalin Zentiva 200 mg kapsuli ibsin
Kull kapsula iebsa fiha 200 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 20 mg lactose monohydrate.
Pregabalin Zentiva 225 mg kapsuli ibsin
Kull kapsula iebsa fiha 225 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 22.5 mg lactose monohydrate.
3
Pregabalin Zentiva 300 mg kapsuli ibsin
Kull kapsula iebsa fiha 300 mg ta’ pregabalin.
Eċċipjent b’effett magħruf
Kull kapsula iebsa fiha wkoll 30 mg lactose monohydrate.
Għal
-lista
sħiħa
ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Kapsula iebsa
Pregabalin Zentiva 25 mg kapsuli ibsin
Għatu griż ċar u korp griż ċar; b’
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 27-07-2015
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 27-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 19-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 27-07-2015

Search alerts related to this product